MINDIMMUNE THERAPEUTICS
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated. Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in... recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.
MINDIMMUNE THERAPEUTICS
Industry:
Biotechnology Neuroscience Pharmaceutical
Founded:
2016-01-01
Address:
Kingston, Rhode Island, United States
Country:
United States
Website Url:
http://www.mindimmune.com
Total Employee:
1+
Status:
Active
Contact:
401-225-4612
Email Addresses:
[email protected]
Total Funding:
1.25 M USD
Technology used in webpage:
Google Apps For Business
Similar Organizations
Aerial BioPharma
Aerial BioPharma is a biopharmaceutical company developing biologics and small molecules for central nervous system issues.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Trend Investment Group
Trend Investment Group investment in Series A - MindImmune Therapeutics
Slater Technology Fund
Slater Technology Fund investment in Seed Round - MindImmune Therapeutics
Official Site Inspections
http://www.mindimmune.com Semrush global rank: 5.23 M Semrush visits lastest month: 1.56 K
- Host name: 198.202.211.1
- IP address: 198.202.211.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MindImmune Therapeutics"
MindImmune Therapeutics, Inc.
MindImmune has made a fundamental discovery that implicates the peripheral immune system in the pathology of Alzheimer’s disease. We are developing a novel therapeutic antibody that …See details»
About - MindImmune Therapeutics, Inc.
MindImmune scientists are at the forefront in discovering mechanisms of neuroinflammation that may be targeted for breakthrough therapeutics for brain disease.See details»
Science - MindImmune Therapeutics, Inc.
MindImmune scientists bring together deep knowledge of both the nervous and immune systems to discover previously unrecognized immune effector mechanisms underlying brain disease. The team is operationalizing this …See details»
MindImmune Therapeutics, Inc. | Alzheimer's Drug Discovery …
Jan 1, 2022 · MindImmune has discovered a way to block this immune cell recruitment and is developing this finding into a new therapeutic approach to Alzheimer's disease. The work …See details»
MindImmune Therapeutics - Crunchbase Company Profile
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and …See details»
MindImmune Therapeutics, Inc. - LinkedIn
MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimer's disease (AD) as initial clinical indication. The company's lead program is an antibody-based...See details»
MindImmune Company Profile 2024: Valuation, Funding
Developer of antibody-based drugs and therapeutics designed to treat diseases of the central nervous system.See details»
Bob Nelson - Vice President of Biology - The Org
In 2016, they became the Ryan Research Professor of Neuroscience at the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island, and they co-founded MindImmune …See details»
MINDIMMUNE THERAPEUTICS TO CONDUCT RESEARCH ON …
Jan 22, 2018 · Based at the University of Rhode Island, MindImmune benefits from an affiliation with the George & Anne Ryan Institute for Neuroscience, Kingston, RI. Seed financing has …See details»
MindImmune Therapeutics Inc. - BIO Investor Forum | BIO
MindImmune is a drug discovery venture focused on neuroinflammation, targeting Alzheimer’s as lead indication.The company is in a vanguard of next generation drug developers aiming to …See details»
MindImmune Therapeutics Announces $12.4 million Series A …
MindImmune Therapeutics Inc., a drug discovery company pioneering a new approach to treat Alzheimer’s disease and other neuro-degenerative conditions, has announced its most recent …See details»
MindImmune Therapeutics - Contacts, Employees, Board …
MindImmune Therapeutics is a pharmaceutical company developing drugs to treat diseases of the central nervous system.See details»
MindImmune Therapeutics Company Profile: Overview and Full …
MindImmune is working on a novel therapeutic antibody to block the immune response attacking the brain, aiming to halt the progression of Alzheimer's disease at its source. The company …See details»
MindImmune Therapeutics CEO and Key Executive Team - Craft
MindImmune Therapeutics's President and Chief Executive Officer, Board Director is Stevin Zorn. Other executives include Frank S. Menniti, Chief Science Officer; Robert B. Nelson, Vice …See details»
Stevin Zorn, PHD, MS, BS - BIO Investor Forum | BIO
Dr. Zorn has more than 27 years drug discovery, drug development experience across a broad range of neuro and psychiatric disorders and across the whole value chain for drug discovery …See details»
MindImmune Therapeutics Appoints Brad Margus and Robert …
Jan 3, 2024 · MindImmune Therapeutics, a pre-clinical stage biopharmaceutical company focused on neuroinflammation targeting Alzheimer’s disease as lead indication, today announced the …See details»
GoLocalProv | Business | RI-Based MindImmune Therapeutics …
Jun 14, 2022 · MindImmune Therapeutics Inc., a Rhode Island-based drug discovery company says that it is “pioneering a new approach to treat Alzheimer’s disease and other neuro …See details»
The MindImmune research enterprise lifts off - ConvergenceRI
May 22, 2018 · The MindImmune value proposition for developing its non-opioid analgesic using P2X7 antagonists is based upon four factors: the “all hands on deck” approach urged by …See details»
News - MindImmune Therapeutics, Inc.
MindImmune Therapeutics Announces $12.4 million Series A Financing. Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery …See details»
Mind-Body Medicine and Immune System Outcomes: A …
Mind-body medicine focuses on the relationships between the brain, mind, body, and behavior, and their effect on health and disease.See details»